[Market Feature] Ildong Pharmaceutical Surges Over 13% Ahead of Oral Obesity Drug Clinical Results

On September 10, Ildong Pharmaceutical is showing strong performance. This is due to heightened investor interest ahead of the announcement of topline results from the Phase 1 clinical trial of its oral obesity treatment, scheduled for the end of this month.

As of 10:14 a.m. on this day, Ildong Pharmaceutical is trading at 24,550 won, up 2,900 won (13.39%) from the previous trading day. The holding company, Ildong Holdings, is also showing strength, rising by 6.51%.

According to the Financial Supervisory Service's electronic disclosure, Ildong Pharmaceutical will release the topline clinical results of its subsidiary Yunovia's oral obesity treatment candidate, 'ID110521156' (ID1156), to institutional investors and others on September 29.

The upcoming topline data will focus on the 200mg dosage group. The key question is whether the high-dose group will demonstrate enhanced weight loss effects while maintaining safety.

In June, Ildong Pharmaceutical presented early clinical data on ID1156 at the American Diabetes Association (ADA 2025). At that time, the 100mg single-dose group showed approximately twice the weight loss effect compared to placebo, drawing significant attention.